MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer

Carcinogenesis

Volumn 33, Issue 1, 2012, Pages 41-48

  Hirata, Hiroshi ^a   Hinoda, Yuji ^b,c   Ueno, Koji ^a   Shahryari, Varahram ^a   Tabatabai, Laura ^b,c   Dahiya, Rajvir ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; LUCIFERASE; MESSENGER RNA; MICRORNA; MIRNA 1826; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN C;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; EPITHELIUM CELL; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WOUND HEALING;

EID: 84855360862     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr239     Document Type: Article

References (36)

1. Pollard,C. et al. (2010) Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert. Rev. Mol. Med., 12, e10.
2. Rouprêt,M. et al. (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur. Urol., 59, 584-594.
3. Proctor,I. et al. (2010) Biomarkers in bladder cancer. Histopathology, 57, 1-13.
4. Pasin,E. et al. (2008) Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev. Urol., 10, 31-43.
5. Stenzl,A. et al. (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur. Urol., 59, 1009-1018.
6. Liebert,M. et al. (1996) Characteristics of invasive bladder cancers: histological and molecular markers. Semin. Urol. Oncol., 14, 62-72.
7. Wallerand,H. et al. (2008) Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. Curr. Opin. Urol., 18, 524-532.
8. Netto,G.J. et al. (2010) Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology, 42, 384-394.
9. Dinney,C.P. et al. (2004) Focus on bladder cancer. Cancer Cell, 6, 111-116.
10. Avruch,J. et al. (2001) Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog. Horm. Res., 56, 127-155.
11. Downward,J. (2003) Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer, 3, 11-22.
12. Boulalas,I. et al. (2009) Activation of RAS family genes in urothelial carcinoma. J. Urol., 181, 2312-2319.
13. Kohno,M. et al. (2006) Targeting the ERK signaling pathway in cancer therapy. Ann. Med., 38, 200-211.
14. Roberts,P.J. et al. (2007) Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene, 26, 3291-3310.
15. Moon,R.T. et al. (2004) WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet., 5, 691-701.
16. Ahmad,I. et al. (2011) Ras mutation cooperates with b-catenin activation to drive bladder tumourigenesis. Cell Death Dis., 2, e124.
17. Ohta,Y. et al. (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer, 81, 54-61.
18. Hashimoto,I. et al. (2001) Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br. J. Cancer, 85, 93-97.
19. Yonemura,Y. et al. (1999) Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin. Cancer Res., 5, 1823-1829.
20. He,Y. et al. (2002) Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst., 94, 819-825.
21. Suzuki,K. et al. (2005) Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int. J. Urol., 12, 152-158.
22. Trang,P. et al. (2008) MicroRNAs as potential cancer therapeutics. Oncogene, 27, S52-S57.
23. Inui,M. et al. (2010) MicroRNA control of signal transduction. Nat. Rev. Mol. Cell. Biol., 11, 252-263.
24. Fabbri,M. et al. (2008) MicroRNAs. Cancer J., 14, 1-6.
25. Wang,X. (2008) miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA, 14, 1012-1017.
26. Hirata,H. et al. (2011) DICKKOPF-4 activates the noncanonical c-Jun-NH2 kinase signaling pathway while inhibiting the Wnt-canonical pathway in human renal cell carcinoma. Cancer, 117, 1649-1660.
27. Yamaguchi,T. et al. (2011) Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int. J. Oncol., 39, 23-31.
28. Choudhary,S. et al. (2011) Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells. J. Cancer Res. Clin. Oncol., 137, 471-480.
29. Fendler,A. et al. (2011) MicroRNAs as regulators of signal transduction in urological tumors. Clin. Chem., 57, 954-968.
30. Zu,X. et al. (2006) Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int., 98, 1090-1093.
31. Xia,H. et al. (2010) miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem. Biophys. Res. Commun., 391, 535-541.
32. Saydam,O. et al. (2009) Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol. Cell. Biol., 29, 5923-5940.
33. Ichimura,A. et al. (2010) MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells. Mol. Pharmacol., 77, 1016-1024.
34. Nakashima,T. et al. (2010) Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS One, 5, e14334.
35. Horstmann,M. et al. (2010) Clinical experience with survivin as a biomarker for urothelial bladder cancer. World J. Urol., 28, 399-404.
36. Ostenfeld,M.S. et al. (2010) miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene, 29, 1073-1084.